{"key":"op_1653_TR","page":{"url":"https://au.bookimed.com/clinics/country=turkey/procedure=actinium-225-therapy/","procedure":{"id":1653,"slug":"actinium-225-therapy","name":"Actinium-225 Therapy","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":46,"iso":"TR","name":"Turkey"},"currency":"USD","data_date":"2026-11-17"},"pages":{"clinics_url":"https://au.bookimed.com/clinics/country=turkey/procedure=actinium-225-therapy/","cost_url":"https://au.bookimed.com/clinics/country=turkey/procedure=actinium-225-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":18300,"to":30000,"avg":{"value":22955,"method":"median","source":"offers"},"us":{"from":60000,"to":110000},"uk":{"from":38000,"to":55000},"by_technique":[{"technique":"PSMA-targeted Ac-225 radioligand","technique_id":"psma-targeted-ac-225","price_from":22955,"currency":"USD","source":"package","offers":2,"date":"2026-11-17"},{"technique":"Somatostatin-receptor-targeted Ac-225 DOTATATE","technique_id":"somatostatin-receptor","price_from":22955,"currency":"USD","source":"package","offers":2,"date":"2026-11-17"}],"by_city":[{"city":"Istanbul","from":18300},{"city":"Antalya","from":14000},{"city":"İzmir","from":12000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"source":"offers","items":[{"tier":"standard","min":17800,"max":17800,"median":17800,"count":1},{"tier":"premium","min":22955,"max":24725,"median":23840,"count":4}]},"comparison":[{"country_iso":"UA","from":6500,"to":11000},{"country_iso":"FR","from":28000,"to":42000},{"country_iso":"GB","from":38000,"to":55000},{"country_iso":"US","from":60000,"to":110000},{"country_iso":"IL","from":28000,"to":42000},{"country_iso":"MX","from":14000,"to":23000},{"country_iso":"DE","from":18000,"to":30000},{"country_iso":"CA","from":14000,"to":26000},{"country_iso":"AE","from":12000,"to":25000},{"country_iso":"TH","from":24000,"to":38000},{"country_iso":"PL","from":8500,"to":15500},{"country_iso":"KR","from":18000,"to":32000},{"country_iso":"CZ","from":14000,"to":22000},{"country_iso":"AT","from":12500,"to":21000},{"country_iso":"ES","from":28000,"to":45000},{"country_iso":"IT","from":18000,"to":30000},{"country_iso":"CN","from":28000,"to":50000},{"country_iso":"AU","from":28000,"to":42000},{"country_iso":"IN","from":5000,"to":8500},{"country_iso":"MY","from":14000,"to":27000},{"country_iso":"VN","from":28000,"to":42000},{"country_iso":"BR","from":22000,"to":38000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":70,"variant":">=15%"},"package":{"included":["Blood tests","Follow-up examination","Transfer airport-clinic-airport","Consultation with a doctor","Biochemistry blood test","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":4,"items":[{"id":96,"name":"Memorial Şişli Hospital","city":"Istanbul","rating":4.6,"reviews_count":437,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":1,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":87,"name":"Anadolu Medical Center","city":"Istanbul","rating":4.6,"reviews_count":544,"accreditations":["Planetree's Gold Certificate","International Accreditation System for Interventional Oncology Services (IASIOS)","Patient choice in Oncology & Hematology Oncology","Patient Choice for Basic Check-up","Johns Hopkins Medicine","Organisation of European Cancer Institutes Certificate","European Society for Medical Oncology","Joint Commission International","International Organization for Standardization","World's Best Hospitals 2026 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Offers specialized Actinium-225 therapy with a dedicated nuclear medicine specialist. JCI accredited and affiliated with Johns Hopkins Medicine. Provides comprehensive care including PSMA PET-CT and kidney function tests.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"69331d0832bd63eea1ffaca2","price":24725,"nights":0,"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program with PSMA PET/CT Scan is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and targeted alpha therapy within a structured treatment pathway. Before therapy, a specialized PSMA PET/CT scan is performed at our hospital to assess PSMA receptor expression and evaluate the extent of disease. Treatment eligibility is determined based on this molecular imaging assessment, ensuring that only suitable patients proceed to Actinium-225 therapy. The treatment uses Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the therapy particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing, PSMA PET/CT imaging, renal evaluation when indicated, administration of Actinium-225 PSMA therapy, and structured medical follow-up. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. Cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure convenient and organized logistics throughout the treatment process."},{"id":"69331d0832bd63eea1ffaca0","price":24725,"nights":0,"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 DOTA ALPHA NEUROENDOCRINE PREMIUM PROGRAM The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a DOTA-based targeting molecule that binds specifically to somatostatin receptor–expressing tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. Before treatment, a specialized DOTA PET/CT scan is performed at our hospital to confirm that the tumor expresses the appropriate receptors and to evaluate disease distribution. Only patients who meet these molecular criteria are selected for Actinium-225 therapy, ensuring a personalized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and full traceability. The treatment package includes nuclear medicine consultation, comprehensive blood testing to assess kidney, liver, and hematologic function, MAG-3 renal scintigraphy during the first cycle if clinically indicated, administration of Actinium-225 DOTA therapy, and structured medical follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, allowing for a smooth and organized treatment experience. This program provides a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled, internationally coordinated clinical framework."},{"id":"69331d0832bd63eea1ffaca1","price":22955,"nights":0,"included":["Follow-up examination","Blood tests","Consultation with a doctor","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 PSMA ALPHA PROSTATE PREMIUM PROGRAM The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging assessment and targeted alpha therapy within a structured and carefully controlled treatment pathway. Prior to therapy, a previously performed PSMA PET/CT scan is carefully reviewed and evaluated to confirm sufficient PSMA receptor expression and assess disease distribution. Treatment eligibility and the final therapy decision are determined based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the treatment particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing to assess kidney, liver, and hematologic function, administration of Actinium-225 PSMA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process."},{"id":"69331d0832bd63eea1ffac9f","price":22955,"nights":0,"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a targeting molecule that binds specifically to neuroendocrine tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected. Prior to therapy, a previously performed DOTA PET scan is carefully reviewed and consulted in order to confirm sufficient receptor expression and determine whether the patient is suitable for treatment. The therapy decision is based on this molecular imaging evaluation, ensuring an individualized and targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings over two decades of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes medical consultation, comprehensive blood testing, renal evaluation when indicated, administration of Actinium-225 DOTA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, ensuring convenient and stress-free logistics during treatment. This program offers a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled and internationally coordinated clinical framework."}]},{"id":426,"name":"Hisar Hospital Intercontinental","city":"Istanbul","rating":4.5,"reviews_count":267,"accreditations":["Joint Commission International","Turkish Medical Association (Türk Tabıplerı Bırliği)","Turkish Medical Association","Patient choice in Oncology & Hematology Oncology","Best patient assistance","Best clinic for radiotherapy"],"rank":3,"has_procedure":true,"why_ranked":"JCI-accredited hospital with an Integrated Oncology department that includes nuclear medicine alongside medical, interventional, and radiation oncology. PYXIS fingerprint medication system prevents errors.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"6ac4a9622083af9548063bf2","price":17800,"price_before_discount":18320,"nights":0,"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Actinium-225 (Ac-225) Targeted Radionuclide Therapy Treatment Description: Actinium-225 targeted radionuclide therapy is an advanced form of nuclear medicine treatment that uses the radioactive isotope Actinium-225 to selectively target and destroy cancer cells. The treatment is generally administered through an intravenous injection and is designed to deliver highly localized radiation to tumor cells while minimizing exposure to surrounding healthy tissues. The treatment is typically considered for selected patients with advanced or metastatic cancers that express specific molecular targets, depending on the patient's diagnosis and eligibility. The Treatment Package Includes: Medical evaluation by a Nuclear Medicine specialist Review of the patient's medical history and previous treatment records Required laboratory and imaging examinations Actinium-225 targeted radionuclide therapy administration Nuclear Medicine specialist consultation and treatment planning Medical monitoring during and after the treatment Post-treatment medical evaluation and follow-up recommendations Important: Patient eligibility and the appropriate Actinium-225 treatment protocol are determined after evaluation of medical records, imaging, laboratory results, and the specific molecular target of the tumor."}]},{"id":276,"name":"Neolife Medical Center","city":"Istanbul","rating":4.7,"reviews_count":19,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":4,"has_procedure":true,"why_ranked":"Actinium-225 is one of five radionuclide therapies offered, alongside Lu-177, I-131, Y-90 and MIBG. JCI-accredited department uses PET/CT and molecular diagnostics for planning.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":4,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":107,"slug":"istanbul","name":"Istanbul","clinics_count":3,"price_from":18300,"profile":{"city_type":"Largest city in Turkey, megacity","access":["Sabiha Gökçen Airport (SAW), 32 km southeast of city center"],"sources":["https://en.wikipedia.org/wiki/Istanbul","https://en.wikipedia.org/wiki/Sabiha_G%C3%B6k%C3%A7en_International_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":382,"slug":"antalya","name":"Antalya","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":14000,"profile":{"city_type":"Major Mediterranean coastal city in Turkey","access":["Antalya Airport (AYT), 13 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Antalya","https://en.wikipedia.org/wiki/Antalya_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":395,"slug":"izmir","name":"İzmir","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":12000,"profile":{"city_type":"Aegean coastal port city in Turkey","access":["Izmir Airport (ADB), 14 km from the city center"],"sources":["https://en.wikipedia.org/wiki/%C4%B0zmir","https://en.wikipedia.org/wiki/Izmir_Adnan_Menderes_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":5,"active_with_related":5,"hospital_nights_median":0,"days_in_country_median":{"status":"missing","reason":"fewer than 10 offers with hotel days"},"top_offers":[{"id":"6ac4a9622083af9548063bf2","clinic_id":426,"clinic_listed":true,"price":17800,"price_before_discount":18320,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Actinium-225 (Ac-225) Targeted Radionuclide Therapy Treatment Description: Actinium-225 targeted radionuclide therapy is an advanced form of nuclear medicine treatment that uses the radioactive isotope Actinium-225 to selectively target and destroy cancer cells. The treatment is generally administered through an intravenous injection and is designed to deliver highly localized radiation to tumor cells while minimizing exposure to surrounding healthy tissues. The treatment is typically considered for selected patients with advanced or metastatic cancers that express specific molecular targets, depending on the patient's diagnosis and eligibility. The Treatment Package Includes: Medical evaluation by a Nuclear Medicine specialist Review of the patient's medical history and previous treatment records Required laboratory and imaging examinations Actinium-225 targeted radionuclide therapy administration Nuclear Medicine specialist consultation and treatment planning Medical monitoring during and after the treatment Post-treatment medical evaluation and follow-up recommendations Important: Patient eligibility and the appropriate Actinium-225 treatment protocol are determined after evaluation of medical records, imaging, laboratory results, and the specific molecular target of the tumor.","is_package":true},{"id":"69331d0832bd63eea1ffac9f","clinic_id":87,"clinic_listed":true,"price":22955,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a targeting molecule that binds specifically to neuroendocrine tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected. Prior to therapy, a previously performed DOTA PET scan is carefully reviewed and consulted in order to confirm sufficient receptor expression and determine whether the patient is suitable for treatment. The therapy decision is based on this molecular imaging evaluation, ensuring an individualized and targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings over two decades of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes medical consultation, comprehensive blood testing, renal evaluation when indicated, administration of Actinium-225 DOTA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, ensuring convenient and stress-free logistics during treatment. This program offers a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled and internationally coordinated clinical framework.","is_package":true}],"packages":[{"id":"6ac4a9622083af9548063bf2","clinic_id":426,"clinic_listed":true,"price":17800,"price_before_discount":18320,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Actinium-225 (Ac-225) Targeted Radionuclide Therapy Treatment Description: Actinium-225 targeted radionuclide therapy is an advanced form of nuclear medicine treatment that uses the radioactive isotope Actinium-225 to selectively target and destroy cancer cells. The treatment is generally administered through an intravenous injection and is designed to deliver highly localized radiation to tumor cells while minimizing exposure to surrounding healthy tissues. The treatment is typically considered for selected patients with advanced or metastatic cancers that express specific molecular targets, depending on the patient's diagnosis and eligibility. The Treatment Package Includes: Medical evaluation by a Nuclear Medicine specialist Review of the patient's medical history and previous treatment records Required laboratory and imaging examinations Actinium-225 targeted radionuclide therapy administration Nuclear Medicine specialist consultation and treatment planning Medical monitoring during and after the treatment Post-treatment medical evaluation and follow-up recommendations Important: Patient eligibility and the appropriate Actinium-225 treatment protocol are determined after evaluation of medical records, imaging, laboratory results, and the specific molecular target of the tumor.","is_package":true},{"id":"69331d0832bd63eea1ffaca2","clinic_id":87,"clinic_listed":true,"price":24725,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program with PSMA PET/CT Scan is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and targeted alpha therapy within a structured treatment pathway. Before therapy, a specialized PSMA PET/CT scan is performed at our hospital to assess PSMA receptor expression and evaluate the extent of disease. Treatment eligibility is determined based on this molecular imaging assessment, ensuring that only suitable patients proceed to Actinium-225 therapy. The treatment uses Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the therapy particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing, PSMA PET/CT imaging, renal evaluation when indicated, administration of Actinium-225 PSMA therapy, and structured medical follow-up. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. Cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure convenient and organized logistics throughout the treatment process.","is_package":true},{"id":"69331d0832bd63eea1ffaca0","clinic_id":87,"clinic_listed":true,"price":24725,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 DOTA ALPHA NEUROENDOCRINE PREMIUM PROGRAM The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a DOTA-based targeting molecule that binds specifically to somatostatin receptor–expressing tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. Before treatment, a specialized DOTA PET/CT scan is performed at our hospital to confirm that the tumor expresses the appropriate receptors and to evaluate disease distribution. Only patients who meet these molecular criteria are selected for Actinium-225 therapy, ensuring a personalized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and full traceability. The treatment package includes nuclear medicine consultation, comprehensive blood testing to assess kidney, liver, and hematologic function, MAG-3 renal scintigraphy during the first cycle if clinically indicated, administration of Actinium-225 DOTA therapy, and structured medical follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, allowing for a smooth and organized treatment experience. This program provides a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled, internationally coordinated clinical framework.","is_package":true},{"id":"69331d0832bd63eea1ffaca1","clinic_id":87,"clinic_listed":true,"price":22955,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Consultation with a doctor","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 PSMA ALPHA PROSTATE PREMIUM PROGRAM The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging assessment and targeted alpha therapy within a structured and carefully controlled treatment pathway. Prior to therapy, a previously performed PSMA PET/CT scan is carefully reviewed and evaluated to confirm sufficient PSMA receptor expression and assess disease distribution. Treatment eligibility and the final therapy decision are determined based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the treatment particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing to assess kidney, liver, and hematologic function, administration of Actinium-225 PSMA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"69331d0832bd63eea1ffac9f","clinic_id":87,"clinic_listed":true,"price":22955,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a targeting molecule that binds specifically to neuroendocrine tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected. Prior to therapy, a previously performed DOTA PET scan is carefully reviewed and consulted in order to confirm sufficient receptor expression and determine whether the patient is suitable for treatment. The therapy decision is based on this molecular imaging evaluation, ensuring an individualized and targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings over two decades of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes medical consultation, comprehensive blood testing, renal evaluation when indicated, administration of Actinium-225 DOTA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, ensuring convenient and stress-free logistics during treatment. This program offers a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled and internationally coordinated clinical framework.","is_package":true}],"related_packages":{"status":"missing","reason":"not_collected"},"other_packages":{"status":"missing","reason":"not_classified"}},"medical":{"indications":["Metastatic castration-resistant prostate cancer with PSMA-positive disease","Progressive neuroendocrine tumors with somatostatin receptor expression"],"contraindications":["Pregnancy or breastfeeding","Severe bone marrow failure","Severely impaired kidney function","Life expectancy under about 3 months","Uncontrolled urinary obstruction or incontinence","Target-negative disease on PET imaging","Active uncontrolled infection"],"operation_hours":{"min":2,"max":6,"unit":"hours","qualifier":"Per cycle including infusion, premedication and post-infusion radiation monitoring."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":3,"max":4,"unit":"visits","qualifier":"One infusion per cycle, typically 3-4 cycles."},"stages":[{"code":"cycle_1","label":"First infusion cycle","after":{"min":0,"max":0,"unit":"days","qualifier":"Start of treatment."}},{"code":"cycle_2","label":"Second infusion cycle","after":{"min":56,"max":60,"unit":"days","qualifier":"Counted from first cycle; about 8 weeks after previous cycle."}},{"code":"cycle_3","label":"Third infusion cycle","after":{"min":112,"max":120,"unit":"days","qualifier":"Counted from first cycle; about 8 weeks after previous cycle."}},{"code":"cycle_4","label":"Optional fourth cycle","after":{"min":168,"max":180,"unit":"days","qualifier":"Counted from first cycle; given if responding and tolerating."}}],"qualifier":"Cycles about 8 weeks apart, adjusted to blood counts and response."},"hospital_nights":{"value":0,"source":"offers","parsed_details":{"min":1,"max":3,"unit":"nights","qualifier":"Per cycle; radiation monitoring and excreta precautions require overnight stays."}},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":3,"max":7,"unit":"days","qualifier":"Per cycle; time to ordinary function depends on fatigue and nausea."},"fly_home_after_days":{"min":2,"max":4,"unit":"days","qualifier":"After each cycle; depends on radiation-safety clearance and travel documentation for detectors."},"back_to_work_days":{"min":2,"max":7,"unit":"days","qualifier":"After each cycle; depends on fatigue, nausea and job demands; radiation-safety advice may limit close contact."},"exercise_resume_weeks":{"min":1,"max":2,"unit":"weeks","qualifier":"Light activity first; strenuous exercise depends on fatigue and blood counts."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"After final cycle; response assessed by PSA trend and PET/CT imaging."},"result_longevity":"Duration of response varies; PSA control often lasts several months to over a year in responders, and disease may progress later.","main_risks":["Dry mouth and salivary gland damage, mainly with PSMA-targeted agents.","Bone marrow suppression: anemia, thrombocytopenia, leukopenia.","Kidney toxicity from renal exposure to radioligands.","Fatigue and nausea.","Radiation exposure of others, requiring radiation-safety precautions."],"complication_rate_pct":{"min":10,"max":30,"unit":"percent","qualifier":"Grade 3-4 adverse events, mainly anemia and other cytopenias; mild dry mouth and fatigue are far more common."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"PSA decline of at least 50% after treatment","value":60,"horizon":"Within 3-6 months of starting therapy","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"No visible scars; only a small cannula puncture site.","pain":"Infusion is painless apart from the cannula. Mild fatigue, nausea, dry mouth or transient bone pain flare may follow.","preparation":["Recent PET/CT confirming target expression","Blood count, kidney and liver tests","Review of prior treatments","Stop interfering medications as advised","Hydration before infusion","Antiemetic premedication","Radiation-safety instructions","Sperm banking discussion if desired"],"recovery_timeline":[{"phase":"Infusion day","description":"Intravenous infusion, then radiation monitoring before discharge.","restrictions":["Follow radiation-safety precautions","Hydrate well"]},{"phase":"Days 1-7","description":"Possible fatigue, nausea and dry mouth; gradual return to routine.","restrictions":["Limit close contact with others and pregnant women","Separate toilet use and flush twice"]},{"phase":"Weeks 2-8","description":"Blood count monitoring, nadir around weeks 4-6; recovery before next cycle.","restrictions":["Avoid heavy exertion if fatigued"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":14,"max":28,"unit":"days","qualifier":"Blood counts and kidney tests, often done locally after each cycle."}},{"purpose":"result_review","requirement":"routine","after":{"min":84,"max":120,"unit":"days","qualifier":"PSA and PET/CT response review after two cycles."}},{"purpose":"result_review","requirement":"routine","after":{"min":200,"max":360,"unit":"days","qualifier":"Counted from first cycle; final response assessment about 3-6 months after last cycle."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C2","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F2","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"A price that sounds too good to be true probably is","scope":"treatment_abroad","source":{"url":"https://www.plasticsurgery.org/news/articles/will-economic-uncertainty-drive-more-patients-overseas-for-plastic-surgery-what-to-consider-and-how-to-stretch-your-dollar-back-home","host":"plasticsurgery.org","quote":"If the price sounds too good to be true, it probably is.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-13","next_check_at":"2027-02-11"},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"PET/CT scan","aliases":["PET/CT scan","PET/CT","PSMA PET/CT"],"kind":"imaging","origin":[{"field":"preparation","text":"Recent PET/CT confirming target expression"},{"field":"initial_assessment_documents","text":"PSMA PET/CT report and images"}],"what_it_checks":{"text":"Shows how well tissues and organs are working","source":{"url":"https://medlineplus.gov/lab-tests/pet-scan/","host":"medlineplus.gov","quote":"A PET (positron emission tomography) scan is a nuclear imaging test that looks at how well your tissues and organs are working.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be asked to fast four to six hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/pet-scan/","host":"medlineplus.gov","quote":"You may be asked to fast (not eat or drink) for four to six hours before the test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T2","name":"Complete blood count","aliases":["Complete blood count","blood count","CBC"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures number and size of blood cells","source":{"url":"https://medlineplus.gov/lab-tests/complete-blood-count-cbc/","host":"medlineplus.gov","quote":"A complete blood count, or CBC, is a group of blood tests that measure the number and size of the different cells in your blood.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function tests","aliases":["Kidney function tests","kidney tests","creatinine"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be told not to eat meat for 24 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/creatinine-test/","host":"medlineplus.gov","quote":"You may be told to not eat meat for 24 hours before your test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T4","name":"Liver function tests","aliases":["Liver function tests","liver tests"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures substances made by the liver in the blood","source":{"url":"https://medlineplus.gov/lab-tests/liver-function-tests/","host":"medlineplus.gov","quote":"Liver function tests (also called a liver panel) use a sample of your blood to measure several substances made by your liver.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Probably fast for 10–12 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/liver-function-tests/","host":"medlineplus.gov","quote":"You will probably need to fast (not eat or drink) for 10-12 hours before the test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T5","name":"PSA test","aliases":["PSA test","PSA"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures PSA, a prostate protein, in the blood","source":{"url":"https://medlineplus.gov/lab-tests/prostate-specific-antigen-psa-test/","host":"medlineplus.gov","quote":"A prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in a sample of your blood.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Avoid sex or masturbating for 24 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/prostate-specific-antigen-psa-test/","host":"medlineplus.gov","quote":"You will need to avoid having sex or masturbating for 24 hours before your PSA test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T6","name":"CT scan","aliases":["CT scan","CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"CT or bone scan reports"}],"what_it_checks":{"text":"Takes detailed pictures of the inside of the body","source":{"url":"https://www.nhs.uk/tests-and-treatments/ct-scan/","host":"nhs.uk","quote":"A CT scan is a test that takes detailed pictures of the inside of your body.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be asked to not eat or drink for several hours before the scan","source":{"url":"https://www.nhs.uk/tests-and-treatments/ct-scan/","host":"nhs.uk","quote":"follow a special diet take certain medicines not eat or drink anything for several hours before the scan (fast) not wear anything that has metal in it, such as jewellery, clothes with zips or poppers, bras or hair clips","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T7","name":"Bone scan","aliases":["Bone scan"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"CT or bone scan reports"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Before some tests, you may need to fast or stop certain medicines","source":{"url":"https://www.nhs.uk/tests-and-treatments/blood-tests/","host":"nhs.uk","quote":"not eat or drink anything other than water (fast) stop taking certain medicines, such as medicines to help prevent blood clots (anticoagulant medicines).","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":2,"max":7,"unit":"days","qualifier":"After each cycle; depends on fatigue, nausea and job demands; radiation-safety advice may limit close contact."},"complication_rate_pct":{"min":10,"max":30,"unit":"percent","qualifier":"Grade 3-4 adverse events, mainly anemia and other cytopenias; mild dry mouth and fatigue are far more common."},"contraindications":["Pregnancy or breastfeeding","Severe bone marrow failure","Severely impaired kidney function","Life expectancy under about 3 months","Uncontrolled urinary obstruction or incontinence","Target-negative disease on PET imaging","Active uncontrolled infection"],"days_in_clinic":{"min":1,"max":3,"unit":"nights","qualifier":"Per cycle; radiation monitoring and excreta precautions require overnight stays."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":1,"max":2,"unit":"weeks","qualifier":"Light activity first; strenuous exercise depends on fatigue and blood counts."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"After final cycle; response assessed by PSA trend and PET/CT imaging."},"fly_home_after_days":{"min":2,"max":4,"unit":"days","qualifier":"After each cycle; depends on radiation-safety clearance and travel documentation for detectors."},"follow_up_visits":[{"purpose":"assessment","after":{"min":14,"max":28,"unit":"days","qualifier":"Blood counts and kidney tests, often done locally after each cycle."},"requirement":"routine"},{"purpose":"result_review","after":{"min":84,"max":120,"unit":"days","qualifier":"PSA and PET/CT response review after two cycles."},"requirement":"routine"},{"purpose":"result_review","after":{"min":200,"max":360,"unit":"days","qualifier":"Counted from first cycle; final response assessment about 3-6 months after last cycle."},"requirement":"routine"}],"indications":["Metastatic castration-resistant prostate cancer with PSMA-positive disease","Progressive neuroendocrine tumors with somatostatin receptor expression"],"main_risks":["Dry mouth and salivary gland damage, mainly with PSMA-targeted agents.","Bone marrow suppression: anemia, thrombocytopenia, leukopenia.","Kidney toxicity from renal exposure to radioligands.","Fatigue and nausea.","Radiation exposure of others, requiring radiation-safety precautions."],"pain":"Infusion is painless apart from the cannula. Mild fatigue, nausea, dry mouth or transient bone pain flare may follow.","preparation":["Recent PET/CT confirming target expression","Blood count, kidney and liver tests","Review of prior treatments","Stop interfering medications as advised","Hydration before infusion","Antiemetic premedication","Radiation-safety instructions","Sperm banking discussion if desired"],"recovery_timeline":[{"phase":"Infusion day","description":"Intravenous infusion, then radiation monitoring before discharge.","restrictions":["Follow radiation-safety precautions","Hydrate well"]},{"phase":"Days 1-7","description":"Possible fatigue, nausea and dry mouth; gradual return to routine.","restrictions":["Limit close contact with others and pregnant women","Separate toilet use and flush twice"]},{"phase":"Weeks 2-8","description":"Blood count monitoring, nadir around weeks 4-6; recovery before next cycle.","restrictions":["Avoid heavy exertion if fatigued"]}],"rehabilitation_days":{"min":3,"max":7,"unit":"days","qualifier":"Per cycle; time to ordinary function depends on fatigue and nausea."},"result_longevity":"Duration of response varies; PSA control often lasts several months to over a year in responders, and disease may progress later.","revision_rate_pct":null,"scars":"No visible scars; only a small cannula puncture site.","sessions_or_stages":{"sessions":{"min":3,"max":4,"unit":"visits","qualifier":"One infusion per cycle, typically 3-4 cycles."},"stages":[{"code":"cycle_1","label":"First infusion cycle","after":{"min":0,"max":0,"unit":"days","qualifier":"Start of treatment."}},{"code":"cycle_2","label":"Second infusion cycle","after":{"min":56,"max":60,"unit":"days","qualifier":"Counted from first cycle; about 8 weeks after previous cycle."}},{"code":"cycle_3","label":"Third infusion cycle","after":{"min":112,"max":120,"unit":"days","qualifier":"Counted from first cycle; about 8 weeks after previous cycle."}},{"code":"cycle_4","label":"Optional fourth cycle","after":{"min":168,"max":180,"unit":"days","qualifier":"Counted from first cycle; given if responding and tolerating."}}],"qualifier":"Cycles about 8 weeks apart, adjusted to blood counts and response."},"success":{"metric":"PSA decline of at least 50% after treatment","value":60,"unit":"percent of patients","horizon":"Within 3-6 months of starting therapy","population":"Metastatic castration-resistant prostate cancer, PSMA-positive, mostly after Lu-177 or chemotherapy","evidence_status":"limited"},"techniques":[{"name":"PSMA-targeted Ac-225 radioligand","suits_whom":"Metastatic castration-resistant prostate cancer with PSMA-positive disease.","recovery":"Overnight or multi-night stay; dry mouth and fatigue common."},{"name":"Somatostatin-receptor-targeted Ac-225 DOTATATE","suits_whom":"Neuroendocrine tumors with receptor-positive disease, often after Lu-177 failure.","recovery":"Overnight or multi-night stay; nausea and fatigue possible."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":2,"max":6,"unit":"hours","qualifier":"Per cycle including infusion, premedication and post-infusion radiation monitoring."},"initial_assessment_documents":["PSMA PET/CT report and images","Recent PSA, blood count, creatinine, liver tests","Biopsy or pathology report","Summary of prior hormone, chemotherapy, Lu-177 treatments","CT or bone scan reports"],"travel_trips":{"min":3,"max":4,"one_trip_possible":false,"qualifier":"One trip per cycle, cycles about 8 weeks apart; typically 3-4 cycles. Each stay is 2-4 days with monitoring."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C2","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F2","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"A price that sounds too good to be true probably is","scope":"treatment_abroad","source":{"url":"https://www.plasticsurgery.org/news/articles/will-economic-uncertainty-drive-more-patients-overseas-for-plastic-surgery-what-to-consider-and-how-to-stretch-your-dollar-back-home","host":"plasticsurgery.org","quote":"If the price sounds too good to be true, it probably is.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-13","next_check_at":"2027-02-11"},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are considering systemic treatment","name":"Systemic chemotherapy","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11919479/","host":"pmc.ncbi.nlm.nih.gov","quote":"Therapeutic alternatives include watch‐and‐wait (including alpha‐blockers to manage hypertension), locoregional therapies, radionuclide treatment, systemic chemotherapy, and molecular targeted therapies.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200},"operation_id":null},{"id":"A2","text":"You are considering a molecular treatment","name":"Molecular targeted therapy","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11919479/","host":"pmc.ncbi.nlm.nih.gov","quote":"Therapeutic alternatives include watch‐and‐wait (including alpha‐blockers to manage hypertension), locoregional therapies, radionuclide treatment, systemic chemotherapy, and molecular targeted therapies.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200},"operation_id":null}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"technique_details":{"status":"ok","items":[{"id":"psma-targeted-ac-225","name":"PSMA-targeted Ac-225 radioligand","how_it_works":{"text":"Radiation is delivered directly to cancer cells, sparing nearby healthy tissue","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11842643/","host":"pmc.ncbi.nlm.nih.gov","quote":"TRT leverages the unique properties of the radionuclides to deliver cytotoxic radiation directly to the cancer cells, minimizing the damage to the surrounding and off-target healthy tissues.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"somatostatin-receptor","name":"Somatostatin-receptor-targeted Ac-225 DOTATATE","how_it_works":{"text":"A peptide with high affinity binds somatostatin receptors on neuroendocrine tumors","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11842643/","host":"pmc.ncbi.nlm.nih.gov","quote":"A widely recognized golden standard as a pharmaceutical within the field of TRT is DOTA-TATE, a small peptide (1436 g/mol) that exhibits high affinity for somatostatin receptors (SSTRs), commonly overexpressed in NETs (Becx et al. 2022 ).","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"PET/CT scan","aliases":["PET/CT scan","PET/CT","PSMA PET/CT"],"kind":"imaging","origin":[{"field":"preparation","text":"Recent PET/CT confirming target expression"},{"field":"initial_assessment_documents","text":"PSMA PET/CT report and images"}],"what_it_checks":{"text":"Shows how well tissues and organs are working","source":{"url":"https://medlineplus.gov/lab-tests/pet-scan/","host":"medlineplus.gov","quote":"A PET (positron emission tomography) scan is a nuclear imaging test that looks at how well your tissues and organs are working.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be asked to fast four to six hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/pet-scan/","host":"medlineplus.gov","quote":"You may be asked to fast (not eat or drink) for four to six hours before the test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T2","name":"Complete blood count","aliases":["Complete blood count","blood count","CBC"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures number and size of blood cells","source":{"url":"https://medlineplus.gov/lab-tests/complete-blood-count-cbc/","host":"medlineplus.gov","quote":"A complete blood count, or CBC, is a group of blood tests that measure the number and size of the different cells in your blood.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function tests","aliases":["Kidney function tests","kidney tests","creatinine"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be told not to eat meat for 24 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/creatinine-test/","host":"medlineplus.gov","quote":"You may be told to not eat meat for 24 hours before your test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T4","name":"Liver function tests","aliases":["Liver function tests","liver tests"],"kind":"lab","origin":[{"field":"preparation","text":"Blood count, kidney and liver tests"},{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures substances made by the liver in the blood","source":{"url":"https://medlineplus.gov/lab-tests/liver-function-tests/","host":"medlineplus.gov","quote":"Liver function tests (also called a liver panel) use a sample of your blood to measure several substances made by your liver.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Probably fast for 10–12 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/liver-function-tests/","host":"medlineplus.gov","quote":"You will probably need to fast (not eat or drink) for 10-12 hours before the test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T5","name":"PSA test","aliases":["PSA test","PSA"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent PSA, blood count, creatinine, liver tests"}],"what_it_checks":{"text":"Measures PSA, a prostate protein, in the blood","source":{"url":"https://medlineplus.gov/lab-tests/prostate-specific-antigen-psa-test/","host":"medlineplus.gov","quote":"A prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in a sample of your blood.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Avoid sex or masturbating for 24 hours before the test","source":{"url":"https://medlineplus.gov/lab-tests/prostate-specific-antigen-psa-test/","host":"medlineplus.gov","quote":"You will need to avoid having sex or masturbating for 24 hours before your PSA test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T6","name":"CT scan","aliases":["CT scan","CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"CT or bone scan reports"}],"what_it_checks":{"text":"Takes detailed pictures of the inside of the body","source":{"url":"https://www.nhs.uk/tests-and-treatments/ct-scan/","host":"nhs.uk","quote":"A CT scan is a test that takes detailed pictures of the inside of your body.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"May be asked to not eat or drink for several hours before the scan","source":{"url":"https://www.nhs.uk/tests-and-treatments/ct-scan/","host":"nhs.uk","quote":"follow a special diet take certain medicines not eat or drink anything for several hours before the scan (fast) not wear anything that has metal in it, such as jewellery, clothes with zips or poppers, bras or hair clips","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T7","name":"Bone scan","aliases":["Bone scan"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"CT or bone scan reports"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Before some tests, you may need to fast or stop certain medicines","source":{"url":"https://www.nhs.uk/tests-and-treatments/blood-tests/","host":"nhs.uk","quote":"not eat or drink anything other than water (fast) stop taking certain medicines, such as medicines to help prevent blood clots (anticoagulant medicines).","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"}}},"techniques":[{"id":"psma-targeted-ac-225","name":"PSMA-targeted Ac-225 radioligand","how_it_works":{"id":"H1","text":"Radiation is delivered directly to cancer cells, sparing nearby healthy tissue","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11842643/","host":"pmc.ncbi.nlm.nih.gov","quote":"TRT leverages the unique properties of the radionuclides to deliver cytotoxic radiation directly to the cancer cells, minimizing the damage to the surrounding and off-target healthy tissues.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Metastatic castration-resistant prostate cancer with PSMA-positive disease.","price_from":22955,"recovery":"Overnight or multi-night stay; dry mouth and fatigue common."},{"id":"somatostatin-receptor","name":"Somatostatin-receptor-targeted Ac-225 DOTATATE","how_it_works":{"id":"H1","text":"A peptide with high affinity binds somatostatin receptors on neuroendocrine tumors","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11842643/","host":"pmc.ncbi.nlm.nih.gov","quote":"A widely recognized golden standard as a pharmaceutical within the field of TRT is DOTA-TATE, a small peptide (1436 g/mol) that exhibits high affinity for somatostatin receptors (SSTRs), commonly overexpressed in NETs (Becx et al. 2022 ).","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Neuroendocrine tumors with receptor-positive disease, often after Lu-177 failure.","price_from":22955,"recovery":"Overnight or multi-night stay; nausea and fatigue possible."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are considering systemic treatment","name":"Systemic chemotherapy","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11919479/","host":"pmc.ncbi.nlm.nih.gov","quote":"Therapeutic alternatives include watch‐and‐wait (including alpha‐blockers to manage hypertension), locoregional therapies, radionuclide treatment, systemic chemotherapy, and molecular targeted therapies.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200},"operation_id":null},{"id":"A2","text":"You are considering a molecular treatment","name":"Molecular targeted therapy","source":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11919479/","host":"pmc.ncbi.nlm.nih.gov","quote":"Therapeutic alternatives include watch‐and‐wait (including alpha‐blockers to manage hypertension), locoregional therapies, radionuclide treatment, systemic chemotherapy, and molecular targeted therapies.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200},"operation_id":null}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Turkey's Ministry of Health publishes lists of authorized healthcare providers and facilitators holding authorization certificates","specialties":[],"source":{"url":"https://shgmturizmdb.saglik.gov.tr/EN-69410/announcements.html","host":"shgmturizmdb.saglik.gov.tr","quote":"Updated lists of healthcare providers and facilitators that have been granted authorization certificates by the Ministry","tier":"government","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-05-11","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK citizen passport holders can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"You can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US ordinary passport holders are exempt from a visa for up to 90 days in any 180-day period in Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Ordinary passport holders are exempted from visa up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 150 days after arrival in Turkey and have at least 1 blank page","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"To enter Turkey, your passport must have an ‘expiry date’ at least 150 days after the date you arrive and at least 1 blank page.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A US passport must be valid for six months beyond the entry date into Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Passports must be valid for six months beyond your entry date.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"prescriptions","audience":"uk","volatile":false,"text":"British prescriptions are not accepted in pharmacies in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"British prescriptions are not accepted in pharmacies in Turkey.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":{"status":"missing","reason":"not_collected"}},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.58,"count":1267,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Actinium-225 therapy in Turkey generally costs between _op_1653_price_from_ and _op_1653_price_to_ per cycle. Final pricing depends on the specific radioligand used, such as PSMA or DOTA, and required diagnostic imaging like PET-CT scans. In the US, similar treatments typically cost _price_compare_US_average_ on average. Patients traveling to Turkey for this procedure can save approximately _price_percent_discount_%. Standard packages usually include nuclear medicine consultations, the radioactive isotope, blood laboratory work, and airport-to-clinic transfers.</p>\n\n<ul>\n<li><strong>PSMA vs DOTA ligands:</strong> Use of specific targeting molecules for prostate or neuroendocrine tumors affects the isotope preparation cost.</li>\n<li><strong>PET-CT imaging:</strong> Baseline and post-therapy scans typically add $900 to $1,500 to the total treatment budget.</li>\n<li><strong>Medical hub location:</strong> Most specialized nuclear medicine centers are located in Istanbul, which serves as the primary gateway.</li>\n<li><strong>International standards:</strong> Facilities following Johns Hopkins Medicine or ESMO standards may price packages 10-15% higher for premium care.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing a center with Joint Commission International (JCI) and European Society for Medical Oncology (ESMO) accreditation ensures top-tier safety. Anadolu Medical Center offers packages starting around $23,000 that include DOTA PET imaging and specialized scintigraphy. This is a smart move because many clinics charge separately for these high-cost diagnostic scans. Patients benefit from American clinical protocols through their Johns Hopkins Medicine affiliation at a fraction of US prices.</p>","faq":[{"q":"Which hospitals in Turkey offer Actinium-225 therapy?","a":"<p>Top Turkish hospitals offering Actinium-225 therapy include Anadolu Medical Center, Memorial Şişli Hospital, and Liv Hospital Ulus. These Istanbul-based facilities utilize specialized nuclear medicine departments for targeted alpha therapy. Most clinics maintain Joint Commission International (JCI) accreditation to ensure rigorous safety standards for radionuclide administration.</p> <ul> <li><strong>Anadolu Medical Center:</strong> Affiliated with Johns Hopkins, providing Ac-225 PSMA and DOTA therapies under expert supervision.</li> <li><strong>Memorial Şişli Hospital:</strong> JCI-accredited facility offering multidisciplinary oncology care and advanced nuclear medicine protocols.</li> <li><strong>Liv Hospital Ulus:</strong> International leader in internal radiation, combining Ac-225 with Lutetium-177 for resistant cancers.</li> <li><strong>Included services:</strong> Packages typically cover PET-CT scans, blood tests, renal scintigraphy, and airport-clinic transfers.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Anadolu Medical Center stands out because its specialists, like Prof. Dr. Kezban Berberoglu, trained at Johns Hopkins. This specific expertise is crucial for Actinium-225, as alpha-emitters require more precise dosing than standard Lutetium treatments. Patients often save up to _price_percent_discount_% compared to US costs for the exact same clinical protocols.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that Actinium-225 is often reserved for cases where Lutetium-177 stopped working. They recommend contacting nuclear medicine departments directly to confirm current isotope availability before traveling.</p>"},{"q":"How does Actinium-225 therapy work?","a":"<p>Actinium-225 therapy is a targeted alpha therapy that destroys cancer cells by delivering high-energy radiation directly to tumors. It uses Actinium-225 isotopes attached to molecules like PSMA or DOTA, which bind specifically to cancer receptors, causing lethal double-stranded DNA breaks while sparing healthy tissue.</p> <ul> <li><strong>Targeted mechanism:</strong> Isotopes attach to antibodies or peptides to seek specific cancer cell receptors.</li> <li><strong>Alpha emission:</strong> Releases 4 alpha particles per atom, providing high-intensity cellular destruction power.</li> <li><strong>Short range:</strong> Radiation travels only 40–100 microns, limiting damage to a few cell diameters.</li> <li><strong>Treatment scope:</strong> Primarily treats metastatic castration-resistant prostate cancer and advanced neuroendocrine tumors.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from Anadolu Medical Center shows that successful Actinium-225 protocols often require preliminary MAG-3 Renal Scintigraphy. This step is vital because it confirms your kidney function can safely process the isotope. High-end Turkish packages include this diagnostic automatically to prevent treatment-induced renal stress.</p> <p><strong>Patient Consensus:</strong> Many patients report a rapid drop in PSA levels within weeks of the first cycle. Common practical advice includes using sugar-free candy and aggressive hydration to protect salivary glands from radiation uptake.</p>"},{"q":"Is Actinium-225 more effective than Lutetium-177?","a":"<p>Actinium-225 is often more effective than Lutetium-177 for advanced, treatment-resistant cancers because it emits alpha particles. These particles cause lethal double-strand DNA breaks that cancer cells cannot repair. While Lutetium-177 remains the standard for bulky tumors, Actinium-225 successfully targets micro-metastases and cases where previous radiation failed.</p> <ul> <li><strong>Radiation mechanism:</strong> Alpha particles deliver high-energy radiation over 0.05–0.1 mm, ensuring intense, localized tumor destruction.</li> <li><strong>DNA damage:</strong> Actinium-225 causes irreversible double-strand breaks, whereas Lutetium-177 often causes repairable single-strand breaks.</li> <li><strong>Resistance recovery:</strong> Patients failing Lutetium-177 therapy frequently see significant PSA drops with targeted Actinium-225 cycles.</li> <li><strong>Precise targeting:</strong> Short-range alpha emission minimizes damage to healthy tissue, protecting organs surrounding microscopic tumor sites.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While Actinium-225 is more potent, Turkish centers like Anadolu Medical Center often suggest starting with Lutetium-177 for initial therapy. Data shows patients save over _price_percent_discount_% in Turkey compared to US costs of _price_compare_US_average_. Saving the high-intensity alpha therapy for later stages or refractory cases helps manage cumulative toxicity while maintaining long-term treatment options.</p> <p><strong>Patient Consensus:</strong> Patients report 60–80% PSA90 responses in cases where other treatments failed. Many emphasize choosing experienced centers like Anadolu to manage side effects like xerostomia during these high-intensity cycles.</p>"},{"q":"What are the expected side effects of Actinium-225 therapy?","a":"<p>Actinium-225 therapy commonly causes xerostomia, or dry mouth, in 70% to 90% of patients because the radiation targets PSMA proteins in salivary glands. Other expected effects include fatigue, mild nausea, and temporary drops in blood cell counts, which typically stabilize within 2 months after treatment.</p> <ul> <li><strong>Salivary gland impact:</strong> Chronic dry mouth usually begins 2 to 4 weeks after the first infusion.</li> <li><strong>Hematological changes:</strong> Temporary declines in platelets or white cells occur in 30% to 50% of cases.</li> <li><strong>Digestive symptoms:</strong> Manageable nausea and appetite loss are common during the first 10 days post-therapy.</li> <li><strong>Kidney function:</strong> Mild creatinine spikes are typically managed with amino acid infusions and specialized monitoring.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Turkish centers like Anadolu Medical Center integrate MAG-3 renal scintigraphy into the first cycle. This specialized scan acts as an early warning system for kidney stress. It allows Nuclear Medicine Specialists like Dr. Kezban Berberoglu to adjust subsequent doses before any permanent impairment occurs.</p> <p><strong>Patient Consensus:</strong> Many patients describe the post-infusion fatigue as extreme tiredness for about 10 days. They strongly recommend starting dry mouth products like xylitol gum early to manage symptoms effectively.</p>"},{"q":"What is the typical treatment timeline in Turkey?","a":"<p>Actinium-225 therapy in Turkey requires an initial 5 to 7-day stay for specialized diagnostics and the first dose. The full treatment course typically spans 6 to 9 months, consisting of 4 to 6 cycles administered at 4 to 8-week intervals at Joint Commission International (JCI) accredited centers.</p> <ul> <li><strong>Pre-treatment workup:</strong> Diagnostics including blood tests and PET/CT scans take approximately 5 days.</li> <li><strong>Cycle frequency:</strong> Patients receive targeted alpha therapy doses every 4 to 8 weeks.</li> <li><strong>Total duration:</strong> Most patients complete the full therapeutic protocol within 6 to 9 months.</li> <li><strong>Travel logistics:</strong> International patients typically stay in Istanbul for 1 week per treatment cycle.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While US patients often face 6-month waitlists for Actinium-225, Turkish centers like Anadolu Medical Center typically provide access within 2 weeks. This speed is critical for late-stage prostate cancer where timing directly impacts outcomes. Coordinating with specialists like Professor Kezban Berberoglu, who trained at Johns Hopkins, ensures American-standard protocols without the Western delay.</p> <p><strong>Patient Consensus:</strong> Patients emphasize budgeting 1 to 2 weeks for the first trip to cover extensive baseline scans. Many recommend confirming isotope availability with the clinic 10 days before flying to avoid customs-related delays.</p>"}],"h2":[{"text":"How it works","kind":"content"},{"text":"How Much Does Actinium-225 Therapy Cost in Turkey in AUD?","kind":"content"},{"text":"Best Actinium-225 Therapy Clinics in Turkey for Australians: 5 Verified Options and AUD Prices","kind":"content"},{"text":"Actinium-225 Therapy Overview in Turkey","kind":"content"},{"text":"Our Doctors","kind":"content"},{"text":"Video Stories from Bookimed Patients","kind":"ui"},{"text":"Reviews about Bookimed: Discover Patients' Insights","kind":"ui"},{"text":"Share this content","kind":"ui"},{"text":"FAQ about Actinium-225 Therapy in Turkey","kind":"content"},{"text":"Get a free consultation","kind":"ui"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[{"field":"medical.hospital_nights","chosen":"offers","offers":0,"parsed_details":{"min":1,"max":3}}]}